Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed hepatocellular carcinoma limited to liver and not suitable for resection, liver transplant, or radiofrequency ablation.~* Intermediate stage (stage B) (according to recognized guidelines) and suitable for TACE therapy~* At least one nodule between \> 2cm and ≤ 15cm in diameter with no vascular invasion or abdominal lymph node or distant metastases.~* Must have 1 tumor which can be measured in 1 dimension according to specified criteria (RECIST and mRECIST) and has not previously been treated with any type of therapy.~* ECOG performance status \< 2cm~* Cirrhotic status of Child-Pugh class A or early B~* HBV-DNA or HBsAg positive at screen or baseline: preventative treatment with anti-viral started 1-2 weeks prior to receiving study drug~Exclusion Criteria:~* Any local and/or investigational drugs within 28 days prior to randomization~* Active bleeding during the last 28 days prior to screening including variceal bleeding~* Prior therapy with mTOR inhibitors~* Tumor burden of \> 60% liver involvement~* Prior systemic or local therapy including TACE except for the first TACE at Day 0), surgery or liver transplantation~* Failed first TACE at Day 0, Cycle 1 for any reason~* Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory)~* Alcohol intake of 80 grams per day~* Undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from surgery~* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- everolimus + TACE (Type: EXPERIMENTAL): everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
- placebo + TACE (Type: PLACEBO_COMPARATOR): Placebo by mouth + transcatheter arterial chemoembolization (TACE)

Based on this trial design, predict the completion outcome and termination type (if applicable).